Feb 14 (Reuters) - CSL Ltd (CSL) :
- STRONG GROWTH IN PLASMA COLLECTIONS AND IN IMMUNOGLOBULINS FRANCHISE IS EXPECTED TO CONTINUE
- HY REPORTED NET PROFIT AFTER TAX ATTRIBUTABLE $1,623.2 MILLION VERSUS $1,760.3 MILLION
- HY UNDERLYING NET PROFIT AFTER TAX AT CONSTANT CURRENCY UP 10% TO US$1.957 BILLION
- INTEGRATION OF CSL VIFOR IS WELL ADVANCED AND THE DELIVERY OF THE SYNERGIES ARE ON TRACK
- DECLARES INTERIM DIVIDEND OF US$ 1.07 PER SHARE
- SEQIRUS IS EXPECTED TO DELIVER ANOTHER PROFITABLE YEAR
- HY TOTAL REVENUE $ 7,183.5 MILLION VERSUS $6,041.2 MILLION
- ANTICIPATED THAT SEQIRUS WILL MAKE A LOSS IN THE SECOND HALF OF THE YEAR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$265.50 |
Change
1.550(0.59%) |
Mkt cap ! $128.5B | |||
| Open | High | Low | Value | Volume |
| $264.45 | $265.88 | $259.33 | $230.1M | 870.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 27 | $265.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $265.80 | 79 | 1 |
View Market Depth
| Last trade - 16.12pm 23/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |